Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort.

ABSTRACT:

Background

Patients with solid organ transplant (SOT) and solid tumors are usually excluded from clinical trials testing immune checkpoint blockers (ICB). As transplant rates are increasing, we aimed to evaluate ICB outcomes in this population, with a special focus on lung cancer.

Methods

We conducted a multicenter retrospective cohort study collecting real data of ICB use in patients with SOT and solid tumors. Clinical data and treatment outcomes were assessed by using retrospective medical chart reviews in every participating center. Study endpoints were: overall response rate (ORR), 6-month progression-free survival (PFS), and grade ≥3 immune-related adverse events.

Results

From August 2016 to October 2022, 31 patients with SOT (98% kidney) and solid tumors were id

SUBMITTER: Remon J 

PROVIDER: S-EPMC11053286 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature